Linagliptin Linagliptin

Linagliptin Linagliptin

Uses of linagliptin

Linagliptin is a dipeptidyl peptidase DPP-4 inhibitor prescribed for the treatment of type 2 diabetes.

Drug form:

This drug is made in the form of 5 mg oral tablets and is known as Tradjenta.

Mechanism of action of linagliptin

It inhibits the mechanism of incretin by inhibiting dipeptidyl peptidase 4, thereby increasing insulin synthesis and release and decreasing glucagon levels.

Pharmacokinetics of linagliptin

The metabolism of this drug is hepatic and it is a substrate of CYP3A4 and P-gP.
The main excretion of linagliptin is through the feces and its half-life is 12 hours.

Side effects of linagliptin
*
Relatively common side effects (10-1%):
Endocrinology and metabolism: hypoglycemia, increased uric acid
Gastrointestinal: Increased serum lipase
Respiratory: nasopharyngitis, cough
Other complications (unspecified percentage):
Skin: Urticaria
Neuromuscular and musculoskeletal: Muscular pain
Respiratory: bronchoconstriction